Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Microvascular hypertensive disease, Long COVID, and end-organ pathology

Hypertension Research volume 46, pages 2247–2248 (2023)Cite this article

A Correspondence to this article was published on 13 July 2023

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cimolai N. Mast cell biology and linkages for non-clonal mast cell activation and autoimmune/inflammatory syndrome induced by adjuvants. SN Compr Clin Med. 2020;2:2310–23.

    Article  Google Scholar 

  2. Cimolai N. Cerebral microvascular and macrovascular disease risk factors and COVID-19 progression. Cerebrovasc Dis. 2021;30:105519.

    Article  Google Scholar 

  3. Garcia JH, Ho K-L. Pathology of hypertensive arteriopathy. Neurosurg Clin N Am. 1992;3:497–507.

    Article  CAS  PubMed  Google Scholar 

  4. Yamaoka-Tojo M. Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19. Biomed J 2020;43:399–413.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Canale MP, Menghini R, Martelli E, Federici M. COVID-19-associated endothelial dysfunction and microvascular injury: from pathophysiology to clinical manifestations. Card Electrophysiol Clin. 2022;14:21–8.

    Article  PubMed  Google Scholar 

  6. Tornhammar P, Jernberg T, Bergström G, Blomberg A, Engström G, Engvall J, et al. Association of cardiometabolic risk factors with hospitalization or death due to COVID-19: population-based cohort study in Sweden. BMJ Open. 2021;11:e051359.

    Article  PubMed  Google Scholar 

  7. Vahey GM, McDonald E, Marshall K, Martin SW, Chun H, Hewlihy R, et al. Risk factors for hospitalization among persons with COVID-19: Colorado. PLoS One. 2021;16:e0256917.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Cimolai N. Untangling the intricacies of infection, thrombosis, vaccination, and antiphospholipid antibodies for COVID-19. SN Compr Clin Med. 2021;3:2093–2108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Funding

Funding was not sought for this publication. There is no third party support including that from the pharmaceutical industry.

Author information

Authors and Affiliations

  1. Faculty of Medicine, The University of British Columbia and, Children’s and Women’s Health Centre of British Columbia, 4480 Oak Street, Vancouver, BC, V6H3V4, Canada

    Nevio Cimolai

Authors
  1. Nevio Cimolai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nevio Cimolai.

Ethics declarations

Conflict of interest

The author declares no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cimolai, N. Microvascular hypertensive disease, Long COVID, and end-organ pathology. Hypertens Res 46, 2247–2248 (2023). https://doi.org/10.1038/s41440-023-01205-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41440-023-01205-1

Keywords

This article is cited by

Search

Advanced search

Quick links